{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclatasvir+%28BMS-790052%29&page=3", "query": { "intervention": "Daclatasvir (BMS-790052)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclatasvir+%28BMS-790052%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclatasvir+%28BMS-790052%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T20:23:16.189Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01830205", "title": "Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2012-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2015-11-16", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 2, "location_summary": "Orlando, Florida • Minneapolis, Minnesota", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830205" }, { "nct_id": "NCT01888900", "title": "New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Chronic Hepatitis C", "Hepatitis C", "Hepatitis C, Chronic" ], "interventions": [ { "name": "DUAL", "type": "DRUG" }, { "name": "QUAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2013-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888900" }, { "nct_id": "NCT01616524", "title": "Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus (HCV)" ], "interventions": [ { "name": "Pegylated interferon lambda (pegIFNλ)", "type": "BIOLOGICAL" }, { "name": "Pegylated interferon alfa-2a (pegIFNα-2a)", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo matching Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2012-07", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 18, "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01616524" }, { "nct_id": "NCT00859053", "title": "Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Insufficiency" ], "interventions": [ { "name": "BMS-790052", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2009-03", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 2, "location_summary": "Anaheim, California • Orlando, Florida", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859053" }, { "nct_id": "NCT02292706", "title": "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" }, { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "Other SOF-Based Regimen", "type": "DRUG" }, { "name": "Ineligible parent treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1609, "start_date": "2014-12-29", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 77, "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02292706" }, { "nct_id": "NCT01492504", "title": "Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1850, "start_date": "2012-02-07", "completion_date": "2018-03-19", "has_results": false, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 50, "location_summary": "Montgomery, Alabama • Beverly Hills, California • Coronado, California + 37 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01492504" }, { "nct_id": "NCT01629732", "title": "Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "BMS-986094", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo for BMS-986094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-03", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629732" }, { "nct_id": "NCT01428063", "title": "Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Asunaprevir", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2011-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-05-27", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 20, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01428063" }, { "nct_id": "NCT01718158", "title": "Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "BIOLOGICAL" }, { "name": "Peginterferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2013-01", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 8, "location_summary": "Long Beach, California • Marietta, Georgia • New York, New York + 5 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Poughkeepsie", "state": "New York" }, { "city": "Allentown", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01718158" }, { "nct_id": "NCT01309932", "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Lambda (pegIFNλ)", "type": "BIOLOGICAL" }, { "name": "BMS-790052 (NS5A Inhibitor)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BMS-650032 (NS3 Protease Inhibitor)", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a (pegIFNα-2a)", "type": "BIOLOGICAL" }, { "name": "Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)", "type": "DRUG" }, { "name": "Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)", "type": "DRUG" }, { "name": "Placebo for Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 165, "start_date": "2011-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-09T20:23:16.189Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Springs", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lutherville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309932" } ] }